Slingshot AI, the New York startup behind the mental-health chatbot Ash, withdrew its app from the United Kingdom in late January 2026 after concluding it could not operate there without running afoul of British medical-device rules. The move marks one of the most visible retreats yet by a well-funded AI therapy company from a major market, and it underscores how unsettled the regulatory ground remains for chatbots that market themselves as emotional support tools rather than clinical treatment.
A Fast Rise Followed by a Sudden Pullback
Ash launched publicly in July 2025 after 18 months of development and testing with roughly 50,000 beta users, according to Slingshot’s own announcements. The company had raised a total of $93 million from investors including Radical Ventures, Forerunner Ventures, a16z, Felicis, and Menlo Ventures, and it positioned Ash as “the first AI designed for therapy” — a free iOS and Android app built to remember prior conversations and adapt its tone to a user’s ongoing mental-health patterns. Just months later, in January 2026, the app disappeared from the UK.
Why Slingshot Says It Left
In an email to UK users reported by STAT News, Slingshot CEO Daniel Reid Cahn wrote that “there isn’t a clear regulatory pathway for wellbeing products like ours — and without that clarity, we can’t operate with confidence.” British regulators, including the Medicines and Healthcare products Regulatory Agency, have been scrutinizing whether apps that engage in emotionally supportive, therapy-styled conversation cross the line into being a regulated medical device, which would require far more rigorous approval than a typical wellness app.
A Pattern Across the Industry
Ash is not the first AI mental-health tool to run into this exact wall. Regulatory uncertainty over where “wellness support” ends and “clinical treatment” begins has already forced other companies to change course, discontinue products, or seek formal medical clearances instead of marketing themselves as general self-help apps. Behavioral-health analysts say the pattern reflects a broader tension: startups want the reach and lighter compliance burden of a consumer wellness product, while regulators increasingly view any tool that responds to expressions of distress, self-harm ideation, or diagnosable symptoms as something closer to a clinical service.
The Case for Caution — and the Case Against It
Mental-health clinicians who support tighter oversight argue that an unregulated chatbot interacting with vulnerable users on emotionally loaded topics needs the same safety scaffolding as any other clinical intervention, including clear escalation protocols for crisis situations. Slingshot and its backers counter that pulling accessible tools out of reach of ordinary users, many of whom cannot get a same-week appointment with a human therapist, creates its own harm by leaving a gap that nothing else fills. The company has said it wants to keep operating in the UK “when there is a clear regulatory path,” suggesting it hopes to return once rules are clarified rather than abandoning the market permanently.
What’s Next for AI Therapy Regulation
The UK withdrawal lands as U.S. states move in the opposite direction of clarity but the same direction of restriction — Illinois, Nevada, Rhode Island, and Maine have all passed laws in 2026 curbing or banning AI-delivered therapy outright. Industry watchers expect more AI mental-health companies to face a choice in the coming year: pursue formal medical-device or software-as-a-medical-device clearances, retreat from markets with ambiguous rules, or rebrand explicitly as non-clinical wellness tools with tighter guardrails on the topics they will engage with. For millions of users who had come to rely on always-available chat support, the practical effect is that access may become less predictable even as the underlying technology keeps improving. Analysts who track the sector expect other AI mental-health companies to study Slingshot’s UK exit closely before deciding whether to expand into similarly ambiguous markets, particularly across the European Union, where the Medical Device Regulation framework has already forced several digital-health startups to either seek formal certification or narrow their marketing claims. Some investors have also begun asking portfolio companies in the space to build contingency plans for sudden market withdrawal, treating regulatory risk as seriously as they would treat a product-safety recall in a more traditional industry. For now, UK users who had built Ash into a daily routine are left searching for alternatives, a small but telling illustration of how quickly access to an AI mental-health tool can vanish when the legal ground beneath it shifts.
